Proton Pump Inhibitor Treatment Stop
Primary Purpose
Dyspepsia
Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
esomeprazole
Helicobacter pylori c-13 breath test
Sponsored by
About this trial
This is an interventional treatment trial for Dyspepsia focused on measuring dyspepsia, discontinuation, Primary health care, Helicobacter pylori, Proton Pump Inhibitor, Histamine-2-receptor-antagonist
Eligibility Criteria
Inclusion Criteria: Use of antisecretory medication for more than 2 months during the last 6 months Exclusion Criteria: Malignity or severe, competing medical or psychiatric disease Esophagitis (proven by endoscopy) Prior complication to peptic ulcer disease Alarm symptoms Pregnancy or lactation Allergy towards esomeprazole Planned hospitalisation during study period
Sites / Locations
- Department of Medical Gastroenterology, Odense University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Placebo Comparator
Arm Label
esomeprazole
placebo drug
Arm Description
Long-term users continue antisecretory medication
Long-term users are treated with placebo
Outcomes
Primary Outcome Measures
Failure of patient perceived symptom control despite treatment with project medication
Secondary Outcome Measures
Gastrointestinal symptoms
Quality of life
GPs and patients satisfaction
Helicobacter pylori status
Resource consumption
Days without symptoms
Use of otc-medication
Sick-leave days
Number of visits to primary and secondary healthcare system
Full Information
NCT ID
NCT00120315
First Posted
July 8, 2005
Last Updated
October 5, 2009
Sponsor
Odense University Hospital
Collaborators
Research Unit of General Practice, Odense, University of Southern Denmark, The Danish Medical Research Council, Apotekerfonden af 1991, AstraZeneca, Danish College of General Practitioners
1. Study Identification
Unique Protocol Identification Number
NCT00120315
Brief Title
Proton Pump Inhibitor Treatment Stop
Official Title
Proton Pump Inhibitor Treatment Stop: Discontinuation of Acid-suppressive Medication Among Long-term Users in a Primary Health Care Setting
Study Type
Interventional
2. Study Status
Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
December 2003 (undefined)
Primary Completion Date
March 2007 (Actual)
Study Completion Date
March 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Odense University Hospital
Collaborators
Research Unit of General Practice, Odense, University of Southern Denmark, The Danish Medical Research Council, Apotekerfonden af 1991, AstraZeneca, Danish College of General Practitioners
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine how many chronic users of antisecretory medication can stop after a test for a bacteria associated with peptic ulcer disease.
This is evaluated in a discontinuation trial.
Detailed Description
Background:
Testing patients with a Helicobacter pylori (Hp) 13C-urea breath test and treatment with eradication of Hp if positive - test-and-eradicate - have proven as effective and safe as prompt endoscopy for management of dyspeptic patients in a primary health care setting. However, empirical treatment with an ulcer-healing drug is often used in dyspeptic patients, as reflected in a growing proportion of long-term users without known ulcer or gastro-oesophageal reflux disease (GORD). This group of patients contributed to 59% of the total use of acid-suppressive medication in the County of Funen in Denmark in 1997.
Aim/purpose:
It is our aim to examine the need for continued medication with prescribed, acid-suppressive drugs in primary health care.
Our secondary objective is to investigate the profile of symptoms, quality of life, Hp-status, consumption of drugs and use of health care services in the same context.
Methods:
To conduct a randomised, placebo-controlled, blinded, clinical discontinuation trial, 500 long-term users of acid-suppressive drugs are identified by general practitioners. Long-term use is defined as treatment for more than 2x28 days during a 6-month period. The patients are included with a 13C-urea Hp-breath test and randomised for treatment with PPI or placebo. Hp-positive patients are treated with an Hp-eradication treatment. The patients are followed for 1 year; the primary outcome is the need for open treatment with acid-suppressive medication due to failing symptom relief despite treatment with the randomised project medication. The patients are to fill in a symptom and medication diary every month for periods of 1 week. Questionnaires are to be given to the patients 3 times during the follow-up period. Medication diaries as well as questionnaires have proven useful in similar studies. The main outcome is analysed using Kaplan-Meier survival estimates analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dyspepsia
Keywords
dyspepsia, discontinuation, Primary health care, Helicobacter pylori, Proton Pump Inhibitor, Histamine-2-receptor-antagonist
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
171 (Actual)
8. Arms, Groups, and Interventions
Arm Title
esomeprazole
Arm Type
No Intervention
Arm Description
Long-term users continue antisecretory medication
Arm Title
placebo drug
Arm Type
Placebo Comparator
Arm Description
Long-term users are treated with placebo
Intervention Type
Drug
Intervention Name(s)
esomeprazole
Intervention Description
esomeprazole, original Nexium, 40 mg pills Up to once a day
Intervention Type
Procedure
Intervention Name(s)
Helicobacter pylori c-13 breath test
Intervention Description
Breath test done at entry to find Helicobacter pylori
Primary Outcome Measure Information:
Title
Failure of patient perceived symptom control despite treatment with project medication
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Gastrointestinal symptoms
Time Frame
12 months
Title
Quality of life
Time Frame
12 months
Title
GPs and patients satisfaction
Time Frame
12 months
Title
Helicobacter pylori status
Time Frame
At enrolement
Title
Resource consumption
Time Frame
12 months
Title
Days without symptoms
Time Frame
12 months
Title
Use of otc-medication
Time Frame
12 months
Title
Sick-leave days
Time Frame
12 months
Title
Number of visits to primary and secondary healthcare system
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Use of antisecretory medication for more than 2 months during the last 6 months
Exclusion Criteria:
Malignity or severe, competing medical or psychiatric disease
Esophagitis (proven by endoscopy)
Prior complication to peptic ulcer disease
Alarm symptoms
Pregnancy or lactation
Allergy towards esomeprazole
Planned hospitalisation during study period
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ove B Schaffalitzky de Muckadell, Professor
Organizational Affiliation
Odense University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Department of Medical Gastroenterology, Odense University Hospital
City
Odense
ZIP/Postal Code
DK-5000
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
26246908
Citation
Zwisler JE, Jarbol DE, Lassen AT, Kragstrup J, Thorsgaard N, Schaffalitzky de Muckadell OB. Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice. Int J Family Med. 2015;2015:175436. doi: 10.1155/2015/175436. Epub 2015 Jul 12.
Results Reference
derived
Learn more about this trial
Proton Pump Inhibitor Treatment Stop
We'll reach out to this number within 24 hrs